<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05068401</url>
  </required_header>
  <id_info>
    <org_study_id>OSSM-BC01</org_study_id>
    <nct_id>NCT05068401</nct_id>
  </id_info>
  <brief_title>Cryopreserved MMUD BM With PTCy for Hematologic Malignancies</brief_title>
  <official_title>A Multi-Center Trial of HLA-Mismatched Unrelated Cryopreserved Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for International Blood and Marrow Transplant Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ossium Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for International Blood and Marrow Transplant Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-phase, multi-center, single arm, prospective study designed to establish the&#xD;
      safety and efficacy of human leukocyte antigen (HLA)-mismatched unrelated cryopreserved&#xD;
      deceased donor bone marrow transplantation (BMT) with post-transplantation cyclophosphamide&#xD;
      for patients with hematologic malignancies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2022</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft Failure</measure>
    <time_frame>Day 35 Post HCT</time_frame>
    <description>Failed hematopoietic engraftment by Day 35 (primary graft failure) exceeding 5% for first 3 patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutrophil and Platelet Recovery</measure>
    <time_frame>Day 35 Post HCT</time_frame>
    <description>Cumulative incidence and kinetics of neutrophil and platelet recovery by Day 35 post-HCT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1-year Post HCT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of acute GVHD and chronic GVHD</measure>
    <time_frame>Day 100 Post HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant Related Mortality</measure>
    <time_frame>1-year Post HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NK, B-, and T-Cell Immune Reconstitution</measure>
    <time_frame>Day 35 Post HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>1-year Post HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival</measure>
    <time_frame>1-year Post HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GVHD Relapse Free Survival (GRFS)</measure>
    <time_frame>1-year Post HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of cytokine release syndrome (CRS)</measure>
    <time_frame>1-year Post HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor Chimerism</measure>
    <time_frame>Day 35 Post HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of BK and cytomegalovirus (CMV) viral infections</measure>
    <time_frame>Day 100 Post HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Disease Relapse/Progression</measure>
    <time_frame>1-year Post HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to donor identification from search request</measure>
    <time_frame>1-year Post HCT</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Length of Stay in Hospital</measure>
    <time_frame>Day 100 Post HCT</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of clinically-significant infections</measure>
    <time_frame>1-year Post HCT</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>T-lymphoblastic Lymphoma</condition>
  <condition>Acute Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Acute Biphenotypic Leukemia</condition>
  <condition>Acute Undifferentiated Leukemia</condition>
  <arm_group>
    <arm_group_label>Regimen A (RIC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine 30 mg/m2/day intravenously (IV) on Days -6, -5, -4, - 3, -2&#xD;
Cy 14.5 mg/kg/day IV on Days -6, -5&#xD;
Total body irradiation (TBI) 200 centigray (cGy) on Day -1&#xD;
Day 0 will be the day of infusion of non-T-cell depleted bone marrow</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen B (FIC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1. Busulfan ≥ 9mg/kg total dose (IV or oral (PO)) on Days -6, -5, -4, -3 2a. Cy 50mg/kg/day IV on Days -2, -1 OR 2b. Fludarabine 30 mg/m2/day IV on Days -6, -5, -4, -3, -2 3. Day 0 will be the day of infusion of non T-cell depleted bone marrow</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen C (FIC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cy 50mg/kg/day IV on Days -5, -4&#xD;
TBI 200cGy twice a day on Days -3, -2, -1&#xD;
Day 0 will be the day of infusion of non- T-cell depleted bone marrow</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone Marrow Hematopoeitic Cell Transplant (HCT)</intervention_name>
    <description>Bone Marrow stem cell graft is infused from a mismatched unrelated deceased donor on Day 0.</description>
    <arm_group_label>Regimen A (RIC)</arm_group_label>
    <arm_group_label>Regimen B (FIC)</arm_group_label>
    <arm_group_label>Regimen C (FIC)</arm_group_label>
    <other_name>Bone Marrow Transplant (BMT)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV pre-transplant as part of conditioning regimen.</description>
    <arm_group_label>Regimen A (RIC)</arm_group_label>
    <arm_group_label>Regimen B (FIC)</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV pre-transplant as part of conditioning regimen.</description>
    <arm_group_label>Regimen A (RIC)</arm_group_label>
    <arm_group_label>Regimen B (FIC)</arm_group_label>
    <arm_group_label>Regimen C (FIC)</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Radiation (TBI)</intervention_name>
    <description>Administered pre-transplant as part of conditioning regimen.</description>
    <arm_group_label>Regimen A (RIC)</arm_group_label>
    <arm_group_label>Regimen C (FIC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Given IV or PO pre-transplant as part of conditioning regimen</description>
    <arm_group_label>Regimen B (FIC)</arm_group_label>
    <other_name>Busuflex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>Mesna is given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide.</description>
    <arm_group_label>Regimen A (RIC)</arm_group_label>
    <arm_group_label>Regimen B (FIC)</arm_group_label>
    <arm_group_label>Regimen C (FIC)</arm_group_label>
    <other_name>Mesnex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Post-Transplantation Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide (50 mg/kg) is administered on Day 3 and on Day 4 post-transplant.</description>
    <arm_group_label>Regimen A (RIC)</arm_group_label>
    <arm_group_label>Regimen B (FIC)</arm_group_label>
    <arm_group_label>Regimen C (FIC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Given at Day 5 with dose adjusted to maintain a level of 5-15 ng/mL through Day 180.</description>
    <arm_group_label>Regimen A (RIC)</arm_group_label>
    <arm_group_label>Regimen B (FIC)</arm_group_label>
    <arm_group_label>Regimen C (FIC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>MMF is given at 15 mg/kg PO TID beginning on Day 5, maximum dose 1g PO TID (maximum daily dose 3g/day) through Day 35</description>
    <arm_group_label>Regimen A (RIC)</arm_group_label>
    <arm_group_label>Regimen B (FIC)</arm_group_label>
    <arm_group_label>Regimen C (FIC)</arm_group_label>
    <other_name>MMF</other_name>
    <other_name>Cellcept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Growth Colony Stimulating Factor</intervention_name>
    <description>G-CSF (filgrastim) or a biosimilar begins on Day 5 at a dose of 5 mcg/kg/day (according to actual body weight) IV or SC (rounding to the nearest vial dose is allowed), until the ANC is ≥ 1,000/mm3 over the course of 3 consecutive days.</description>
    <arm_group_label>Regimen A (RIC)</arm_group_label>
    <arm_group_label>Regimen B (FIC)</arm_group_label>
    <arm_group_label>Regimen C (FIC)</arm_group_label>
    <other_name>Filgrastim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Recipient Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated informed consent form&#xD;
&#xD;
          2. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          3. Male or female, aged ≥ 15 and &lt; 71 years (Note: HIV-negative subjects with MDS must be&#xD;
             aged &lt;50 at the time of signing the informed consent form)&#xD;
&#xD;
          4. Diagnosed with a. Acute leukemias or T-LBL in 1st of subsequent CR i. ALL or T-LBL as&#xD;
             defined by the following:&#xD;
&#xD;
        1. &lt; 5% blasts in the bone marrow 2. Normal maturation of all cellular components in the&#xD;
        bone marrow 3. No currently active extramedullary disease (EMD) (e.g., central nervous&#xD;
        system (CNS), soft tissue disease) 4. ANC ≥ 1,000/mm3 ii. AML defined by the following:&#xD;
&#xD;
          1. &lt; 5% blasts in the bone marrow&#xD;
&#xD;
          2. No blasts with Auer rods&#xD;
&#xD;
          3. Normal maturation of all cellular components in the bone marrow&#xD;
&#xD;
          4. No currently active EMD (e.g., CNS, soft tissue disease)&#xD;
&#xD;
          5. ANC ≥ 1,000/mm3 iii. ABL/AUL defined by the following:&#xD;
&#xD;
          1. &lt; 5% blasts in the bone marrow&#xD;
&#xD;
          2. Normal maturation of all cellular components in the bone marrow&#xD;
&#xD;
          3. No currently active EMD (e.g., CNS, soft tissue disease)&#xD;
&#xD;
          4. ANC ≥ 1,000/mm3 b. MDS, fulfilling the following criteria: i. Subjects with de novo&#xD;
             MDS who have or have previously had Intermediate-2 or High-risk disease as determined&#xD;
             by the IPSS. Current Intermediate-2 or High- risk disease is not a requirement. ii.&#xD;
             Subjects must have &lt; 20% bone marrow blasts, assessed within 60 days of informed&#xD;
             consent. iii. Subjects may have received prior therapy for the treatment of MDS prior&#xD;
             to enrollment&#xD;
&#xD;
          5. Performance status: Karnofsky or Lansky score ≥ 60%&#xD;
&#xD;
          6. Adequate organ function defined as:&#xD;
&#xD;
               1. Cardiac: LVEF at rest ≥ 35% (RIC cohort) or LVEF at rest ≥ 40% (FIC cohort), or&#xD;
                  LVFS ≥ 25%&#xD;
&#xD;
               2. Pulmonary: DLCO, FEV1, FVC ≥ 50% predicted by pulmonary function tests (PFTs).&#xD;
                  DLCO value may be corrected or uncorrected for hemoglobin.&#xD;
&#xD;
               3. Hepatic: total bilirubin ≤ 2.5 mg/dL, and ALT, AST, and ALP &lt; 5 x ULN (unless&#xD;
                  ALT, AST, and/or ALP are disease related)&#xD;
&#xD;
               4. Renal: SCr within normal range for age (see table 5.1A). If SCr is outside normal&#xD;
                  range for age, CrCl &gt; 40 mL/min/1.73m2 must be obtained (measured by 24-hour (hr)&#xD;
                  urine specimen or nuclear glomerular filtration rate (GFR), or calculated GFR (by&#xD;
                  Cockcroft-Gault formula for those aged ≥ 18 years; by Original Schwartz estimate&#xD;
                  for those &lt; 18 years).&#xD;
&#xD;
          7. Subjects ≥ 18 years of age must have the ability to give informed consent according to&#xD;
             applicable regulatory and local institutional requirements. Legal guardian permission&#xD;
             must be obtained for subjects &lt; 18 years of age.&#xD;
&#xD;
        Recipient Exclusion Criteria:&#xD;
&#xD;
        1. Suitable HLA-matched related or 8/8 allele matched (HLA-A, -B, -C, -DRB1) unrelated&#xD;
        donor available that is not an Ossium product 2. Autologous HCT &lt; 3 months prior to the&#xD;
        time of signing the informed consent form 3. Pregnancy or lactation 4. Treatment with an&#xD;
        investigational drug or other interventional GVHD clinical trials 5. Current uncontrolled&#xD;
        bacterial, viral or fungal infection (currently taking medication with evidence of&#xD;
        progression of clinical symptoms or radiologic findings) 6. Prior allogeneic HCT 7. Primary&#xD;
        myelofibrosis or myelofibrosis secondary to essential thrombocythemia or polycythemia vera&#xD;
        8. Subjects with MDS may not receive RIC and must be &lt; 50 years of age at the time of&#xD;
        signing the informed consent form 9. Any condition(s) or diagnosis, both physical or&#xD;
        psychological, or physical exam finding that in the investigator's opinion precludes&#xD;
        participation&#xD;
&#xD;
        Donor Inclusion Criteria:&#xD;
&#xD;
          1. Those who donated after brain death (DBD) or after circulatory death (DCD)&#xD;
&#xD;
          2. Sex and Age: Both male and female donors age 7-55 years old who have consented for&#xD;
             organ and tissue procurement for research purposes.&#xD;
&#xD;
          3. Maximum warm ischemia time: 8 hours&#xD;
&#xD;
          4. Maximum cold ischemia time: 50 hours (defined as all the time after vertebral bodies&#xD;
             are placed on wet ice)&#xD;
&#xD;
          5. Must undergo eligibility screening procedures, including an evaluation of medical&#xD;
             history and relevant social behavior, per 21 CFR 1271 and the FDA's Guidance for&#xD;
             Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular&#xD;
             and Tissue-Based Products (HCT/Ps) (2007)&#xD;
&#xD;
             Donor Exclusion Criteria:&#xD;
&#xD;
        1. Evidence of septicemia, viremia, or bacteremia at time of death or positive blood&#xD;
        culture 2. Sexually transmitted infections acquired, treated, or untreated within the last&#xD;
        12 months 3. Active or past history of neurological diseases such as Alzheimer's disease,&#xD;
        dementia, or Creutzfeldt-Jakob disease (CJD) 4. Rabies 5. If the colon or esophagus was&#xD;
        perforated during recovery 6. A positive/reactive result on the infectious disease panel&#xD;
        (see serology requirements)&#xD;
&#xD;
        The serology testing requirements for donor eligibility for the infectious disease&#xD;
        organisms:&#xD;
&#xD;
        • Hepatitis B Surface Antigen (HBsAg)&#xD;
&#xD;
        • Hepatitis B Core Antibody (HBc Ab)&#xD;
&#xD;
          -  Human T-Lymphotropic Virus Type I &amp; II (HTLV I/II)&#xD;
&#xD;
          -  Human Immunodeficiency Virus 1 and 2 Plus O Antibody (HIV 1/2 +O Ab)&#xD;
&#xD;
          -  Hepatitis C Virus Antibody (Anti-HCV)&#xD;
&#xD;
          -  Syphilis (RPR or STS)&#xD;
&#xD;
          -  HIV1/HCV/HBV Nucleic Acid Testing (NAT)&#xD;
&#xD;
          -  West Nile Virus (WNV) Nucleic Acid Testing&#xD;
&#xD;
          -  Trypanosoma cruzi (T. cruzi) Anti-T. cruzi Assay (Chagas)&#xD;
&#xD;
          -  Cytomegalovirus&#xD;
&#xD;
          -  Epstein-Barr Virus (EBV VCA IgG or EBNA)&#xD;
&#xD;
          -  Toxoplasmosis (IgG)&#xD;
&#xD;
        Donors must have negative or nonreactive results to all tests except for HBc Ab, CMV or&#xD;
        EBV, where a reactive or nonreactive result is conditionally acceptable. However, donors&#xD;
        may be ruled out if they pose a significant risk to researchers or the processing&#xD;
        environment.&#xD;
&#xD;
        7. Recipient positive anti-donor HLA antibodies against a mismatched HLA in the selected&#xD;
        donor determined by either:&#xD;
&#xD;
          1. a positive crossmatch test of any titer (by complement-dependent cytotoxicity or flow&#xD;
             cytometric testing) or&#xD;
&#xD;
          2. the presence of anti-donor HLA antibody to any HLA locus (HLA-A, -B, -C, - DRB1,&#xD;
             -DQB1, -DQA1, -DPB1, -DPA1) with mean fluorescence intensity (MFI) &gt;3000 by solid&#xD;
             phase immunoassay&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>71 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffery Auletta, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Study Protocol Officer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shannon Clark, MS</last_name>
    <phone>6124025362</phone>
    <email>sclark2@nmdp.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erin Leckrone</last_name>
    <phone>763-406-5124</phone>
    <email>eleckron@nmdp.org</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Myelodysplastic Syndromes</keyword>
  <keyword>Preleukemia</keyword>
  <keyword>Precursor Cell Lymphoblastic Leukemia-Lymphoma</keyword>
  <keyword>Leukemia, Lymphocytic, Chronic, B-Cell</keyword>
  <keyword>Leukemia, Myeloid, Acute</keyword>
  <keyword>Leukemia, Biphenotypic, Acute</keyword>
  <keyword>Immunoproliferative Disorders</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Bone Marrow Diseases</keyword>
  <keyword>Precancerous Conditions</keyword>
  <keyword>Leukemia, Lymphoid</keyword>
  <keyword>Leukemia, B-Cell</keyword>
  <keyword>Leukemia, Myeloid</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Mesna</keyword>
  <keyword>Busulfan</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Total Body Irradiation</keyword>
  <keyword>Mycophenolate mofetil</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>Unrelated Donors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Leukemia, Biphenotypic, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

